Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes.

[1]  Cheng-fang Hu,et al.  Association of Nonalcoholic Fatty Liver Disease With Osteoporotic Fractures: A Cross-Sectional Retrospective Study of Chinese Individuals , 2018, Front. Endocrinol..

[2]  C. Byrne,et al.  Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults , 2018, British Medical Journal.

[3]  T. Umehara,et al.  Nonalcoholic fatty liver disease with elevated alanine aminotransferase levels is negatively associated with bone mineral density: Cross-sectional study in U.S. adults , 2018, PloS one.

[4]  E. Tapper,et al.  Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD , 2018, Nature Reviews Gastroenterology & Hepatology.

[5]  L. Idolazzi,et al.  New Strategies for the Prevention and Treatment of Systemic and Local Bone Loss; from Pathophysiology to Clinical Application. , 2018, Current pharmaceutical design.

[6]  C. Byrne,et al.  Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus , 2018, Nature Reviews Endocrinology.

[7]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[8]  S. Upala,et al.  Nonalcoholic fatty liver disease and osteoporosis: a systematic review and meta-analysis , 2017, Journal of Bone and Mineral Metabolism.

[9]  K. J. Kim,et al.  Significant liver fibrosis assessed using liver transient elastography is independently associated with low bone mineral density in patients with non-alcoholic fatty liver disease , 2017, PloS one.

[10]  A. Schwartz,et al.  Mechanisms of diabetes mellitus-induced bone fragility , 2017, Nature Reviews Endocrinology.

[11]  Herbert Tilg,et al.  Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases , 2017, Gut.

[12]  P. Vestergaard,et al.  MECHANISMS IN ENDOCRINOLOGY: Diabetes mellitus, a state of low bone turnover - a systematic review and meta-analysis. , 2017, European journal of endocrinology.

[13]  S. Lee,et al.  Association between bone mineral density and nonalcoholic fatty liver disease in Korean adults , 2016, Journal of Endocrinological Investigation.

[14]  J. Kountouras,et al.  Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease , 2016, Journal of Bone and Mineral Metabolism.

[15]  M. Rubin,et al.  Advanced Glycation Endproducts and Bone Material Strength in Type 2 Diabetes. , 2016, The Journal of clinical endocrinology and metabolism.

[16]  Xin Gao,et al.  The association of liver fat content and serum alanine aminotransferase with bone mineral density in middle-aged and elderly Chinese men and postmenopausal women , 2016, Journal of Translational Medicine.

[17]  S. Shim,et al.  Association of nonalcoholic fatty liver disease with bone mineral density and serum osteocalcin levels in Korean men , 2016, European journal of gastroenterology & hepatology.

[18]  C. Byrne,et al.  Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. , 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[19]  A. Lonardo,et al.  Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link? , 2015, Journal of Endocrinological Investigation.

[20]  C. Byrne,et al.  NAFLD: a multisystem disease. , 2015, Journal of hepatology.

[21]  Y. Huang,et al.  Wnt signaling in liver fibrosis: progress, challenges and potential directions. , 2013, Biochimie.

[22]  S. Qu,et al.  Low Bone Mineral Density in Chinese Adults with Nonalcoholic Fatty Liver Disease , 2013, International journal of endocrinology.

[23]  C. Byrne,et al.  Nonalcoholic fatty liver disease and reduced serum vitamin D(3) levels. , 2013, Metabolic syndrome and related disorders.

[24]  L. Idolazzi,et al.  Sclerostin and DKK1 in Primary Hyperparathyroidism , 2013, Calcified Tissue International.

[25]  G. Silecchia,et al.  Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus , 2012, Hepatology.

[26]  L. Idolazzi,et al.  Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[27]  G. Casazza,et al.  Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis. , 2012, Gastroenterology.

[28]  Yu Xu,et al.  Association between nonalcoholic fatty liver disease (NAFLD) and osteoporotic fracture in middle-aged and elderly Chinese. , 2012, The Journal of clinical endocrinology and metabolism.

[29]  I. Kamel,et al.  Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta‐analysis , 2011, Hepatology.

[30]  D. Black,et al.  Clinical Practice. Postmenopausal Osteoporosis. , 2005, The New England journal of medicine.

[31]  R. Marcus.  Post-menopausal osteoporosis. , 2002, Best practice & research. Clinical obstetrics & gynaecology.

[32]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[33]  J. Kanis,et al.  Perspectives assessment of involutional bone loss: Methodological and conceptual problems , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[34]  L. Henry,et al.  NAFLD AND NASH: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018 .

[35]  Y. Lang,et al.  Diabetes mellitus and risk of hip fractures: a meta-analysis , 2015, Osteoporosis International.